5-二氰亚甲基-4-二环丙亚甲基-3-[1-(2,5-二甲基-3-呋喃基)亚乙基]四氢呋喃-2-酮的合成

报道俘精酸酐类化合物(E/Z)4-二环丙亚甲基-3-[1-(2,5-二甲基-3-呋喃基)亚乙基]四氢呋喃-2,5-酮的拆分,及(E)和(Z)-5-二氰亚甲基-4-二环丙亚甲基-3-[1-(2,5-二甲基-3-呋喃基)亚乙基]四氢呋喃-2-酮4(E)和4(Z)的合成,并对它们的光致变色特性进行了初步研究。     

2-[2-(4, 6-二甲基)-嘧啶基]-4-苯基-1, 2, 4-恶二唑烷-3, 5-二酮的合成

异氰酸苯酯和N-[2-(4, 6-二甲基)-嘧啶基]-羟胺(5)反应生成1-[2-(4, 6-二甲基)-嘧啶基]-1-羟基-3-苯基脲(6)。化合物(6)在三乙胺存在下和氯甲酸乙酯反应生成2-[2-(4, 6-二甲基)-嘧啶基]-4-苯基-1, 2, 4-恶二唑烷-3, 5-二酮(1)。     

6,7-亚甲二氧基-9-甲基-1(2H,4H)-吖啶酮衍生物的合成

以5-芳基-1,3-环基环己二酮为原料合成了8个未见报道的吖啶酮衍生物,其结构均经元素分析,IR和^1H NMR光谱确证。其中3-呋喃基-6,7-亚甲二氧基-9-甲基-1(2H,4H)-吖啶醇对一些肿瘤细胞有抑制作用。     

基于呋喃-3-酮配体的铜(Ⅱ)配合物的合成及其晶体结构

以4-甲酰基-2,2,5,5-四甲基四氢呋喃-3-酮和间甲基苯胺为原料,经缩合反应制得配体(Z)-4-[(间甲苯胺基)亚甲基]-2,2,5,5-四甲基二氢呋喃-3(2H)-酮(L);以Cu(CH_3COO)_2为铜源,L经配位反应合成了一个新型的铜(Ⅱ)配合物[Cu(L)_2]_n(I),其结构经FT-IR,X-射线单晶衍射和元素分析表征。I属单斜晶系,P2(1)/c空间群,晶胞参数a=11.361 3(19)?,b=24.564(4)?,c=12.026(2)?,α=γ=90°,β=110.452(3)°,V=3 144.6(9)?~3,Dc=1.226 g·cm~(-3),Z=4,R_1=0.051 5,wR_2=0.113 2。     

芳亚甲基双(3-羟基-5,5-二甲基-2-环己烯-1-酮)类化合物的合成

在水溶剂中,酸性离子液体[bmim][HSO4]可以有效地催化芳香醛与5,5-二甲基-1,3-环己二酮反应3～5h,得到产率为76%～86%的芳亚甲基双(3-羟基-5,5-二甲基-2-环己烯-1-酮)类化合物.该反应产物后处理简单,催化剂可以回收利用.催化剂在循环使用五次时对产物的收率影响不大,是一种环境友好的绿色合成方法.     

α-二酮的铟促水相烯丙基化研究

以6,7-十二烷二酮(或1,2-环烷基二酮)和3-碘-2-碘甲基-1-丙烯为原料,铟粉为催化剂,在水相中经烯丙基化反应合成了4个新型的单烯丙基化产物[7-羟基-7-(2-碘甲基-烯丙基)-十二烷-6-酮和2-羟基-2-(2-碘甲基-烯丙基)-环烷酮]和3个新型的双烯丙基化产物{4-亚甲基-1,2-二戊基-1,2-环戊二醇,2-羟基-2-[2-(1-羟基-2-羰基-环癸基甲基)-烯丙基]-环癸酮和2-羟基-2-[2-(1-羟基-2-羰基-环十二基甲基)-烯丙基]-环十二烷酮},其结构经1H NMR,IR和HR-MS表征。     

2′-羟基-1′,3′-苯撑二亚甲基冠醚的合成

2,6-二羟甲基-4-氯苯甲醚(3)和2,6-二羟甲基-4-苯基苯甲醇(4)与三缩四乙二醇和四缩五乙二醇的二对甲苯磺酸酯在含有叔丁醇钾的无水四氢呋喃中反应生成甲氧基冠醚5—7。后者与过量无水碘化锂在无水吡啶中廻流有选择性地除去甲基而不影响大环苄醚基的破裂生成三种2’-羟基-1’,3’-亚苯基二甲基冠醚8—10,产率为85—89％。     

由2-(1, 3-亚丙二硫基)亚甲基脂环酮出发合成共轭的烯酮硫缩醛

2-(1, 3-亚丙二硫基)亚甲基脂环酮(2')与甲基、丁基、仲丁基Grignard试剂经1, 2-加成反应得产物3, 3在酸的催化下脱水生成共轭的烯酮硫缩醛类化合物4。本实验提供了一条经由α-羰基烯酮环二硫代缩醛类化合物合成在有机合成中有重要应用的共轭烯酮硫缩醛类化合物的新途径。     

(Z)-3,3-二甲基-1-(1H-1,2,4-三唑-1-基)-2-丁酮肟(5-芳基-1,3,4-噁二唑-2-基)甲基醚的合成和抑菌活性

以3,3-二甲基-1-（1H-1,2,4-三唑基）-2-丁酮肟为原料,经醚化、肼解及腙化3步反应得到（E）-N'-（取代苯亚甲基）-2-[（Z）-3,3-二甲基-1-（1H-1,2,4-三唑-1-基）丁基-2-亚甲氨氧基]乙酰肼（3a~3u）,化合物3与二乙酸碘苯（IBD）反应,合成了21个（Z）-3,3-二甲基-1-（1H-1,2,4-三唑-1-基）-2-丁酮肟-（5-芳基-1,3,4-噁二唑-2-基）甲基醚（4a~4u）,化合物4的化学结构经核磁共振谱、高分辨质谱和元素分析确证.采用单晶X射线衍射仪测定了化合物4c的晶体结构.抑菌活性测试结果表明,在500 mg/L浓度下,化合物4k,4f,4j和4n对纹枯病菌的防效率分别为70.9%,60.2%,60.0%和60.6%;在25 mg/L浓度下,化合物4b,4c,4d和4e对菌核病菌的抑制率为71.8%~76.9%.     

2-[2-(4,6-二甲基)-嘧啶基]-4-苯基-1,2,4-噁二唑烷-3,5-二酮的合成

异氰酸苯醇和N-[2-(4,6-二甲基)-嘧啶基]-羟胺(5)反应生成1-[2-(4,6-二甲基)-嘧啶基]-1-羟基-3-苯基脲(6)。化合物(6)在三乙胺存在下和氯甲酸乙醇反应生成2-[2-(4,6-二甲基)-嘧啶基]-4-苯基-1,2,4-噁二唑烷-3,5-二酮(1)。     

1-Trimethoxysilylmethyl-and 1-(2,8,9-trioxa-5-aza-1-silabicyclo[3.3.3]undecan-1-ylmethyl)-1,1-dimethyl-2-(3-alkoxy-3-oxopropyl)hydrazinium halides

Previously unknown 1,1-dimethyl-1-trimethoxysilylmethyl-2-(3-alkoxy-3-oxopropyl)hydrazinium and 1,1-dimethyl-1-(2,8,9-trioxa-5-aza-1-silabicyclo[3.3.3]undecan-1-ylmethyl)-2-(3-alkoxy-3-oxopropyl)-hydrazinium halides were synthesized, and physiological activity of 2-(3-ethoxy-3-oxopropyl)-1,1-dimethyl-1-(2,8,9-trioxa-5-aza-1-silabicyclo[3.3.3]undecan-1-ylmethyl)hydrazinium chloride and bromide was studied.     

Five-Membered 2,3-dioxoheterocycles: XCV. Recyclization of 4-benzoyl-5-phenylfuran-2,3-dione at the action of substituted 1,3,3-trimethyl-2-azaspiro[4.5]dec-1-enes. Crystal and molecular structure of substituted 5-(2-azaspiro[4.5]dec-1-ylidene)cyclopent-3-ene-1,2-dione

4-Benzoyl-5-phenylfuran-2,3-dione reacts with 2′,5′,5′-trimethyl-4′,5′-dihydro-4H-spiro[naphthalene-1,3′-pyrrol]-4-one and 8-(2-methoxy-5-methylphenyl)-1,3,3,9-tetramethyl-2-azaspiro[4.5]deca-1,7-dien-6-one with the formation of (Z)-3-benzoyl-5-(5′,5′-dimethyl-4-oxo-4H-spiro[naphthalene-1,3′-pyrrolidin]-2′-ylidene)-4-phenylcyclopent-3-ene-1,2-dione, whose structure was proved by XRD analysis, and of (Z)-3-benzoyl-5-{8-(2-methoxy-5-methylphenyl)-3,3,9-trimethyl-6-oxo-2-azaspiro[4.5]dec-7-en-1-ylidene}-4-phenylcyclopent-3-ene-1,2-dione.     

Synthesis of a 6-aryloxymethyl-5-hydroxy-2,3,4,5-tetrahydro-[1H]-2-benzazepin-4-one: a muscarinic (M3) antagonist

A synthesis of the racemic 6-aryloxymethyl-5-hydroxy-2,3,4,5-[1H]-2-tetrahydrobenzazepin-4-one , for evaluation as a muscarinic (M(3)) antagonist, is described. 2-[2-tert-Butyldimethylsilyloxymethyl-6-(2,6-dimethoxyphenoxymethyl)phenyl]propan-2-ol was prepared from 2,6-dimethyl-1-bromobenzene and taken through to N-[3-(2,6-dimethoxyphenoxymethyl)-2-(propen-2-yl)phenyl]methyl-N-prop-2-enyl 2-nitrobenzene sulfonamide . However, attempts to cyclise this diene by alkene metathesis were unsuccessful, the open-chain alkene being the only product isolated in yields of up to 70%. In a second approach to the 6-aryloxymethyl-5-hydroxytetrahydrobenzazepin-4-one, methyl (Z)-3-[2-(1-tert-butyldimethylsilyloxymethyl)-6-(1,6-dimethoxyphenoxymethyl)phenyl]but-2-enoate was converted into (Z)-3-[2-hydroxymethyl-6-(2,6-dimethoxyphenoxymethyl)phenyl]but-2-enyl 2-nitrobenzene sulfonamide which was cyclised under Mitsunobu conditions to the corresponding 2,3-dihydro-[1H]-2-benzazepine . The structure of this was confirmed by an X-ray crystal structure of its 2-(4-bromophenylsulfonyl) analogue , and functional group modification including hydroxylation, attachment of the requisite side-chain at C(2) and further oxidation gave the target compound which was assayed for muscarinic (M(3)) activity.     

Synthesis of 1-[3-methyl-2(3H)-benzazolon-5- or 6-yl]-4-{4-[cis-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl-methyl)-1,3-dioxolan-4-yl]methyleneoxyphenyl}piperazines

Reactions of 3-methyl-6-[4-(4-hydroxyphenyl)-1-piperazinyl]-2(3H)-benzoxazolone, 3-methyl-6-[4-(4-hydroxy-phenyl)-1-piperazinyl]-2(3H)-benzothiazolone and 1,3-dimethyl-5-[4-(4-hydroxyphenyl)-1-piperazinyl]-2(3H)-benzimidazolone with cis-{[2-(2,4-dichlorophenyl) -2-(1H-imidazol-1-ylmethyl)]-1,3-dioxolan-4-yl}methyl meth-anesulfonate in the presence of sodium hydride furnish the title compounds.     

Crystal Structure of Methyl 3- (2-chlorophenyl )-3- (5, 5-dimethyl-3-hydroxy-2-cyclohexene- 1-one-2-yl) propionate

1INTRODUCTIONInorganicsolidsupportsascatalystshavebeenwellstudied,becauseoftheirap-plicationsinorganicsynthese('~".Recently,wehavereportedtheKnoevenagelcon-densationcatalysedbyKF-Al,O,['i.Inthispaper,wediscussedthecrystalstruc-tureofthetitlecomPoundsynthesizedbythereactionof2-chlorobenzaldehydey5,5-dimethyl-1,3-cyclohexanedioneandisopropylidenemalonateinmethanolcatalyzedbyKF-Alzo,'Inordertoconfirmthestructureofthetitlecompound,theX-raycrys-tallOgraphicstudywascarriedout.2EXPER1MEN…     

On the synthesis of geometric isomers of 2-methyl (or phenyl)-4-[α-arylethylidene]-5(4H)-oxazolones

Several Z-2-methyl(or phenyl)-4-[α-arylethylidene]-5(4H)-oxazolones 3Z, 4Z were prepared. The results obtained were compared by diazomethane insertion and condensation procedure. In order to synthesize E-2-phenyl-4-[α-arylethylidene]-5(4H)-oxazolones 4E hydrogen bromide isomerization in dry benzene was used.     

Unusual reactions of 5,5-dimethyl-2-(indenyl-2)-3-pyrazolidinone with acetylenedicarboxylates

[reaction: see text] Reaction of 5,5-dimethyl-3-pyrazolidinone (1) with 2-indanone (2) gave 5,5-dimethyl-2-(1H-indenyl-2)-3-pyrazolidinone (3) instead of the expected azomethine imine 4. Although reaction of 2-substituted 3-pyrazolidinones with acetylenedicarboxylates usually gives ring expansion products, such as 1,2-diazepines, treatment of 3 with dialkyl acetylenedicarboxylates (5, R = Me; 6 R = Et) resulted in the formation of rel-(7aR,12aS)-6,7-bis(alkoxycarbonyl)-3,4-dihydro-4,4-dimethyl-7aH-indano[1,2-b]pyrrolo[1,2-a]pyrimidin-2-ones (7, R = Me; 9, R = Et) as major products and 3,4-bis(alkoxycarbonyl)-7,7-dimethyl-2-(indenyl-2)-6,7-dihydro-2H,6H-1,2-diazepin-5-ones (8, R = Me: 10, R = Et) as minor products.     

Synthesis and crystal structure of optically active 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dim ethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate (NZ-105).

(S)-2-[Benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2, 6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate ((S)-NZ-105) and R isomer were synthesized through the fractional crystallization of (S)-2-Methoxy-2-phenylethyl 5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2, 6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate. Calcium antagonism activity was found to reside in the S isomer from single crystal X-ray diffraction analysis.